Can Özbal, PureHoney Technologies president and CEO and his team were the principals of BIOCIUS Life Sciences before it was acquired by Agilent in 2011, and with it, the RapidFire technology.
The employees worked as part of Agilent until 2014 before leaving nearly two years ago to start their “new venture” based around the technology as a CRO, Özbal told us.
“You can buy the instruments from Agilent, but you can also outsource experiments to PureHoney as a contract research business,” he said.
Once again working with Agilent, Özbal expalined the collaboration should be “very successful.”
“We have a different corporate structure, but the connections are there, and are very strong and deep,” he added. “We’re very excited to be working with Agilent again.”
The tool was originally developed for label-free high-throughput screening. Today, RapidFire/MS is used in applications ranging from ADME-Tox, proteomics, metabolomics, clinical research to in vivo functional assays.
Through the co-marketing agreement, PureHoney Technologies and RapidFire MS instrumentation will work to develop new workflows for pharma and biopharma research, in addition to forensic toxicology and metabolomics analysis.